Drug maker Alvotech announced this week that it has raised $300 million, through a private bond offering, that it will used to continue its growth, refinance debt, and further develop its biosimilar pipeline.
Drug maker Alvotech announced this week that it has raised $300 million, through a private bond offering, that it will used to continue its growth, refinance debt, and further develop its biosimilar pipeline.
In a statement, Alvotech’s founder, Robert Wessman, said that the cash infusion would help the company to further its biosimilar development and fund its clinical studies, “the results of which bring significant potential for healthcare providers around the world to drive healthcare savings and expand patient access to high-quality biosimilars.”
The Iceland-headquartered biosimilar developer, founded in 2013 by Wessman, has 6 monoclonal antibodies in its pipeline. To date, the company has not disclosed the specific biosimilars that it is developing, saying only that the products target cancer, autoimmune diseases, inflammatory conditions, and other disease states. Alvotech has previously said that it anticipates the first of its products to be brought to market by 2020.
Last month, Fuji Pharma announced that it had acquired a 4.2% stake—worth approximately $50 million—in Alvotech. That acquisition came shortly on the heels of an announcement that the 2 companies would partner to commercialize Alvotech’s entire pipeline of biosimilars in the Japanese market.
Through the partnership agreement, Alvotech will be responsible for the development and supply of biosimilars, while Fuji Pharma will be responsible for filing the products with Japan’s regulatory agency, as well as the commercialization of the approved biosimilars.
Additionally, in 2018, Alvotech forged an agreement with Changchung High & New Technology Industries Group to enable the development, manufacture, and commercialization of biosimilars in China.
In order to keep pace with its anticipated supply needs, Alvotech recently built a new state-of-the-art biopharmaceutical facility in Reykjavik, Iceland, which was granted licensure by the Icelandic Medicines Agency, together with the Irish Health Products Regulatory Authority, in 2018. Additionally, the company owns manufacturing plants in Germany and Switzerland.
Other key shareholders in Alvotech include controlling shareholder Aztiq Pharma AB, led by Wessman, and generic pharmaceutical company Alvogen.
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.